Slide 1: 1H FY25 Results Investor Presentation
2 September 2025 ASX ANNOUNCEMENT 1H FY25 Results Investor Presentation Attached are the 1H FY25 Results Investor Presentation slides which will be delivered at a conference call with the investment community, including a Q&A session, at 10am today. To listen to the conference call, please register
Slide 2: 1H FY25 Results
1H FY25 Results 2 September 2025
Slide 3: The Radiology of the Future
01 THE RADIOLOGY OF THE FUTURE delivered into your hands
Slide 4: One Company with two businesses democratizing access to medical imaging expertise
02 One Company with two businesses aimed at democratizing access to medical imaging expertise Software Business Radiology Services Medical imaging software (RIS, Radiology services, primarily PACS, universal viewer, AI) in Colombia
Slide 5: Some Figures
03 8.9M +549 3.4K Imaging Installed Monthly Specialist studies year sites users Some 6.3M 25 58 Figures Users of the Partners Net Promoter patient portal Score
Slide 6: Year Overview Trends
04 5 YEAR OVERVIEW TRENDS TRENDS LAST 5 YEARS 2020 2021 2022 2023 2024 10 600 9 500 8 7 400 6 5 300 4 200 3 2 100 1 - 0 2020 2021 2022 2023 2024 Studies Per Year (M) 6 7.8 8.0 8.4 8.9 Portal Users (M) - 2.5 3.5 6.4 6.7 Sites 270 386 449 485 525
Slide 7: IMEXHS Global Presence
05 IMEXHS GLOBAL PRESENCE Our certifications reaffirm our dedication to excellence across multiple geographies.
Slide 8: 1H FY25 Financial Highlights
06 1H FY25 FINANCIAL HIGHLIGHTS Sales Revenue1 Annual Recurring Underlying Revenue (ARR) EBITDA3 Up 4% yoy $13.7m Up 11% yoy $32.8m Flat vs pcp Up 7% on a constant Up 7% on a constant $0.3m currency basis2 currency basis Cash Debt $2.5m $1.3m vs $2.1m at 31 vs $1.2m at 31 December 2024 December 2024
Slide 9: 1H FY25 Business Unit Results
07 1H FY25 BUSINESS UNIT RESULTS Total 1H $M Software Radiology Corporate FY25 Revenue 4.7 9.0 - 13.7 Underlying 1.3 0.3 (1.3) 0.3 EBITDA ARR 11.9 20.9 - 32.8 Software primarily relates to sales of IMEXHS Radiology includes RIMAB along with other Enterprise and growing IMEXHS Cloud business services
Slide 10: Progress in ARR
08 PROGRESS IN ARR ARR AS AT 30 JUNE 2025 → $32.8m, up 11% vs 30 Jun-24: → $32.8m, up 9% vs 31 Dec-24 → $11.9m from Software, up 20% vs $9.9m at 31 Dec-24; and → $20.9m from Radiology services, up 4% vs $20.1m at 31 Dec-24. (1) Constant currency basis assumes that historical results at each year end
Slide 11: Delivering diagnoses that transform the lives of 500 million people
09 Delivering We are dedicated to offering tailored diagnoses that technology and service solutions to hospitals, clinics, and diagnostic centres, transform the with a clear emphasis on improving lives of 500 radiology efficiency and lowering costs by million people. up to 80%.
Slide 12: Software Business Strategy - IMEXHS
10 SOFTWARE BUSINESS STRATEGY- IMEXHS LATAM Efficiency Leadership Trust & SaaS Reliability Model
Slide 13: Strategic Pillars
11 STRATEGIC PILLARS Driving sustainable, efficient, and profitable growth STRATEGIC PILLARS Consolidate leadership in Scale Driving automation and cost LATAM SaaS MODEL efficiency
Slide 14: Software Business Highlights - IMEXHS
12 SOFTWARE BUSINESS HIGHLIGHTS - IMEXHS SOFTWARE ARR ENTERPRISE WINS PARTNERS CHANNEL → Q1: $183k Clínica Occidente + → $11.9m ARR and $4.7m Hospital Moncaleano. → 25 partners in 15 countries. revenue at 1H FY25. → Q2: $206k INNN México + $490K Diodiagnostico → 33% of 1H NARR generated by → Driven
Slide 15: Software Product
13 SOFTWARE PRODUCT Product Progress New Value Proposition → Launch of Aquila+ → Fully Deployed • A fully integrated multitenant RIS-PACS AI-enhanced • Cybersecurity: ISO 27001 certification achieved for suite. the Aquila+, and R&D process. • Transcription & validation module implemented. • Quick an
Slide 16: Aquila AI Agent
sh a” > A Agent AQUILA Al Optimize your work with our Al agent, your best ally.
Slide 17: Viewer with deepc AI
Viewer with deepc Al
Slide 18: Cost & Margin Improvement in 1H
16 COST & MARGIN IMPROVEMENT IN 1H AREA KEY ACTION Costs (storage and processing) reduced, Cloud improvements in gross margin. Focus on key processes and value R&D / Product creation. Structured plan to Optimized structure, impact on fixed strengthen Finance costs. EBITDA & Margins Sales Admin Adjus
Slide 19: New Software Pricing Model
17 NEW SOFTWARE PRICING MODEL Market Pricing Projected Upselling Segmentation Model Financial Opportunity Strategy Innovation Impact → Four Distinct → Customer-Centric → Pricing Model → Secondary Revenue Segments Pricing Benefits → Leveraging Aquila+ → Customized Value → Implementation → Profit Marg
Slide 20: Software Business - IMEXHS 2025-2026
18 SOFTWARE BUSINESS - IMEXHS 2025 - 2026 Commercial Execution Expansion Plan New segmentation + pricing model 2025 Focus on Partners Program Boost 2026 Entry plans Pipeline & Sales Conversion Enhanced Partner Support
Slide 21: Radiology Services - RIMAB
19 RADIOLOGY SERVICES - RIMAB • Outsorcing • Revenue $9.0m • Teleradiology. • EBITDA $281k • Outpatient clinics. • ARR $20.9m • Mobile units. Business Financial Model Snapshot Operating Tech Footprint Integration • 35 sites. • Diagnostics • Specialized Staff - Precision. 160 radiologists. • Services
Slide 22: Strategy - Radiology Business - RIMAB
20 STRATEGY – RADIOLOGY BUSINESS - RIMAB Profitability Working Capital Context Colombia’s Healthcare Sector RIMAB ACTIONS Structural crisis, pending reforms. Continue improving margins. Regulatory uncertainty, increased financial stress Strategic customers selection and active on payors. contract ne
Slide 23: Strategic Outlook
21 STRATEGIC OUTLOOK Software Business Radiology Services Margins Improvement Regional consolidation and • Dynamic pricing assessment and growth renegotiation. • Commercial and marketing focus • Cost control via AI and on selected segments. automation. Pricing optimization (new Working capital prote
Slide 24: FY25 Guidance
22 FY25 GUIDANCE Guidance The Company expects to achieve the following for FY25: → Revenue in the range $27.5m to $28.2m - up 4.0 to 6.6% vs prior year. → Underlying EBITDA in the range $1.3m to $1.6m - up $0.8m to $1.1m vs prior year.
Slide 25: Thank You
THANK YOU
Slide 26: Q&A
Q&A
Slide 27: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 28: 1H FY25 Results
1H FY25 Results 2 September 2025